Truist Financial upgraded shares of Caribou Biosciences, and MarketBeat provided average rating and price target.
1 report, 1 independent
Updated Jul 1
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Truist Financial upgraded shares of Caribou Biosciences, and MarketBeat provided average rating and price target.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Caribou Biosciences
company in Berkeley, United States
Nothing else this week.
-
Truist Financial
American bank holding company, formerly known as BB&T Corporation
- Financial firms including Bank of America, Morgan Stanley, and Truist Financial adjusted price targets and ratings for Somnigroup International Inc.
- Rating firms Raymond James Financial, Cantor Fitzgerald, and Truist Financial issued updates, including buy ratings and price targets, for First Industrial Realty Trust on June 19, 2026.
-
MarketBeat
American personal finance blog
- Jefferies Financial Group began coverage, Morgan Stanley set a high price target, and Keefe, Bruyette & Woods increased price objectives, with MarketBeat reporting the average stock rating.
- Scotiabank raised its price target and Bank of America upgraded its rating on May 27, 2026, with MarketBeat aggregating the data.
Related events
- Truist Financial lifted its price target and Jefferies Financial Group reissued a buy rating for Pediatrix Medical Group.
- Financial firms including Truist, RBC, TD Cowen, and Jefferies issued various rating updates on October 30, 2026.
- MarketBeat provided consensus rating data for TuHURA Biosciences, Inc. on November 1, 2026.
- MarketBeat reported the consensus rating for Diaceutics PLC.
- Truist Financial raised its target price and Amundi increased its position in Harmony Biosciences shares.